Pharmos Corporation Announces Successful Completion Of Proof-of-concept Clinical Trial Of Levotofisopam For The Treatment Of Gout
RAPID AND SIGNIFICANT REDUCTION IN URIC ACID OBSERVED IN ALL SUBJECTS ISELIN, N.J., May 17, 2012 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) today announced that it has successfully completed a proof-of-concept clinical trial using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout. This phase 2a trial was conducted at the Duke Clinical Research Unit of Duke University and the principal investigator was John Sundy, MD, PhD, an expert and key opinion ...continuedPARS pharmaceutical pharma Healthcare
Related News:
- Pharmos Provides Update on Ongoing Clinical Trial of Levotofisopam for the Treatment of Gout
- Pharmos Announces Dosing of First Patients in Clinical Trial of Levotofisopam for the Treatment of Gout
- Pharmos Corporation Reports First Quarter 2012 Results
- Lightlake Therapeutics Inc. Announces Positive Preliminary Phase II Clinical Trial Results of Binge Eating Disorder Treatment
- Advaxis Announces Cancer Research UK Initiates Phase 1/2 Clinical Trial of ADXS-HPV for the Treatment of Head and Neck Cancer
- Nile Therapeutics Announces Positive Clinical Trial Results Evaluating the Subcutaneous Infusion of Cenderitide
- Further Analysis Reveals Double Digit Hair Growth in RepliCel’s First-in-man Clinical Trial
United-Guardian Announces 17% Increase in Mid-Year Dividend
HAUPPAUGE, N.Y., May 17, 2012 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (Nasdaq:UG) announced today that the company's Board of Directors, at its meeting on May 16, 2012, declared a cash dividend of $0.42 per share, which will be paid on June 18, 2012 to all stockholders of record as of the close of business on June 4, 2012. This represents a 17% increase over the $0.36 per share semi-annual dividend paid in the first half of 2011. Ken Globus, President of United-Guardian, stated, "With record sale...continuedUG pharma biotech pharmaceutical
Related News:
- LyondellBasell Board Authorizes Dividend Increase of 60 Percent
- United-Guardian Reports Record Sales and Earnings
- Kellogg Company Declares Regular Dividend of $0.43 Per Share and Announces Plans for 2 Percent Dividend Increase
- K-Bro Announces Increase and Declares May Dividend
- United Corporations Limited Announces Dividend on Common Shares
- Sensient Technologies Corporation Announces Dividend Increase
- HollyFrontier Corporation Announces Special Dividend And 50 Percent Increase In Regular Dividend
Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
MALVERN, Pa. and MAHWAH, N.J., May 17, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) ("Auxilium") and FCB I LLC ("FCB") today announced that the United States Patent and Trademark Office ("USPTO") has issued U.S. Patent No. 8,178,518 covering, among other things, Testim® 1% testosterone gel, marketed by Auxilium under license from FCB. The newly issued patent, which claims certain pharmaceutical compositions comprising testosterone, is expected to expire in April 2023. Auxili...continuedAUXL XTLS pharmaceuticals pharmaceutical biotech
Related News:
- Interventional Spine(, Inc. Announces Issuance of Patent No. 8,105,382, Covering the Company’s Unique Expandable Interbody Fusion Device, the Opticage(tm)
- Interventional Spine(, Inc. Announces Issuance of Patent No. 8,105,382, Covering the Company’s Unique Expandable Interbody Fusion Device, the Opticage(tm)
- Opsona Therapeutics announces the issuance of new patent from the European Patent Office (EPO) covering the development and use of an antibody directed against Toll-like Receptor TLR-2
- Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Ltd. Enter a Collaboration Agreement for XIAFLEX( in Canada, Australia, Brazil and Mexico
- NanoViricides Announces Issuance of a Fundamental Patent in the USA
- General Patent Corporation Secures Settlement with U.S. Government in Patent Lawsuit in the Court of Claims
- BioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX( in Canada, Australia, Brazil and Mexico
Alkermes plc Reports Results for Fiscal 2012 and Provides Expectations for Fiscal 2013
Alkermes plc (NASDAQ: ALKS) today reported financial results for its fourth quarter and fiscal year ended March 31, 2012, and provided financial expectations for its fiscal year 2013, which will be the first full fiscal year of the combined company, Alkermes plc (Alkermes), following the completion of the merger of Alkermes, Inc. with Elan Drug Technologies (EDT) on Sept. 16, 2011. Fourth Quarter Fiscal 2012 Highlights Total revenues for the fourth quarter increased more than 155% to $130.5...continuedALKS pharmaceutical biotechnology amylin
Related News:
- Alkermes’ Corporate Presentation to be Webcast at the 30th Annual J.P. Morgan Healthcare Conference
- Elan Reports Fourth Quarter and Full-Year 2011 Financial Results
- Cipher Reports Fiscal 2011 Financial Results
- Norcraft Companies, L.P. Reports Fourth Quarter and Fiscal 2011 Results
- Patient Safety Technologies Reports Fourth Quarter and Fiscal 2011 Results
- Krispy Kreme to Release Fourth Quarter and Fiscal Year 2012 Results and Discuss Management’s Outlook for Fiscal 2013 on March 20, 2012
- The Gymboree Corporation Reports Fourth Quarter and Fiscal Year 2011 Results
Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
Drs. Kathy D. Miller and Hope S. Rugo join SAB WORCESTER, Mass. and TORONTO, May 15, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT), in anticipation of the transition into pivotal Phase III trials, is pleased to announce today that the expertise of the Scientific Advisory Board (SAB) of its wholly-owned subsidiary, Antigen Express, Inc., has been expanded by the addition of two globally recognized experts in clinical trial research and immuno-therapeutic treatment...continuedGNBT GNTB biotechnology pharmaceutical Healthcare
Related News:
- Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
- Generex Announces Establishment of a Scientific Advisory Board for Antigen Express
- Dr. Carlo Croce joins Trovagene as Scientific Consultant and Member of the Company’s Scientific Advisory Board
- Computer Vision Systems Laboratories Corp. Announces the Appointment of Dr. David Fiorella to Its Scientific Advisory Board
- AnaptysBio Adds Dr. David L. Lacey and Dr. Michael Gallatin to Therapeutic Advisory Board
- Los Angeles Syndicate of Technology Announces its Portfolio Company, Sanguine BioSciences, Inc. Makes Major Appointment to Scientific Advisory Board
- PRVCY Appoints Robert DeSantis Chairman of the Advisory Board
3SBio Inc. Announces Unaudited First Quarter 2012 Results
Net revenues grew 24.5% year-on-year to RMB147.2 million (US$23.4 million) Reiterates 2012 net revenues guidance of US$99-US$108 million SHENYANG, China, May 13, 2012 /PRNewswire-Asia/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the first quarter ended March 31, 2012. First Quarter 2012 ...continuedSSRX 沈阳 pharmaceuticals pharmaceutical
Related News:
- 3SBio Inc. Schedules Unaudited Fourth Quarter and Full Year 2011 Results
- 3SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2011 Results
- Acorn International Reports Fourth Quarter and Full Year 2011 Unaudited Financial Results
- Jiayuan Announces Fourth Quarter and Full Year 2011 Unaudited Financial Results
- China Mass Media Reports Fourth Quarter and Full Year 2011 Unaudited Financial Results
- China Dredging Group Co., Ltd. Reports Unaudited Third Quarter 2011 Results
- Sky-mobi Limited Announces Unaudited Financial Results for the Fiscal Third Quarter 2012
Lannett Company Adds Paul Taveira to Board of Directors
Lannett Company, Inc. (NYSE Amex: LCI), a manufacturer of generic pharmaceuticals, today announced the appointment of Paul Taveira to its board of directors, expanding the company’s board to eight members. Taveira, 52, currently serves as chief executive officer of A&D Environmental Services Inc., an environmental and industrial services company. Earlier, he was managing partner of Precision Source LLC, a manufacturer of precision parts for various industries across the United States. P...continuedLCI pharma pharmaceutical Healthcare
Related News:
- Richard Thaler, Jr. Named to Gordon Brothers Group’s Board of Directors
- Trinity Industries, Inc. Adds Melendy Lovett to its Board of Directors
- Northcore Appoints Paul Godin as New Chairman of the Board of Directors
- Prism adds Bob Parsons to the Board of Directors
- Carnival Corporation & plc Adds Kelly-Ennis to Board of Directors, Announces Quarterly Dividend
- NMC Resource (TSX VENTURE:NRC) Appoints Paul Matysek to the Board of Directors
- Rare Element Announces Randall J. Scott & Paul Zink Appointed to the Board of Directors
Momenta to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
CAMBRIDGE, Mass., May 11, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its presentation at the Bank of America Merrill Lynch 2012 Health Care Conference will be webcast on Wednesday, May 16 at 5:00 p.m. PT (8:00 p.m. ET). The audio webcast of the presentation will be available live on the "Investors" section of the company's website located at www.momentapharm...continuedMNTA pharmaceuticals pharmaceutical Healthcare
Related News:
- Momenta to Present at the 2012 Citi Global Health Care Conference
- Zimmer Holdings to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
- MAXIMUS to Present at the Bank of America Merrill Lynch Health Care Conference on May 17
- HeartWare Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference to be Webcast
- Alphatec Spine to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
- Puma Biotechnology to Present at BofA Merrill Lynch Health Care Conference
- Arthur J. Gallagher & Co. to Present at The Bank of America Merrill Lynch Insurance Conference
Echo Therapeutics Announces First Quarter 2012 Financial Results
PHILADELPHIA, May 11, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced financial results for the quarter ended March 31, 2012. Echo's Quarterly Report on Form 10-Q as filed with the SEC is available through Echo's website at www.echotx.com. Recent Corpo...continuedECTE Healthcare pharma pharmaceutical
Related News:
- Echo Therapeutics, Inc. Announces 2011 Financial Results
- Echo Global Logistics Announces First Quarter 2012 Earnings Release and Conference Call Scheduled for Thursday, April 26, 2012
- TeleTech Announces First Quarter 2012 Financial Results
- BankFinancial Corporation Reports Financial Results for the First Quarter 2012 and Will Host a Conference Call and Webcast on May 8, 2012
- Chemtura Reports First Quarter 2012 Financial Results
- Enterprise Purchases Property to Expand ECHO Crude Oil Storage Facility
- Equinox Holdings, Inc. Announces Date for Release of First Quarter 2012 Financial Results and Earnings Conference Call
PolyMedix Provides Update on PMX-60056 Program
RADNOR, Pa., May 10, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care conditions, today announced an update on the development status of its anticoagulant reversing agent, PMX-60056. PolyMedix has stopped enrollment in two clinical trials for PMX-60056: a Phase 2 clinical trial for reversing the anticoagulant activity of unfractionated heparin (UFH) in patients undergoing percutan...continuedPYMX cd45 pharmaceutical Healthcare
Related News:
- PolyMedix Announces Positive Results From Phase 2 Clinical Trial With PMX-30063 First-in-Class Defensin-Mimetic Antibiotic
- PolyMedix to Review Full Results From Phase 2 Clinical Trial With PMX-30063 Defensin-Mimetic Antibiotic
- Verified Clinical Trials System Implemented At Leading Global Contract Research Organization To Improve Participant Safety And Data Integrity
- Proteonomix Updates Progress on Multiple Programs
- ACT Announces Data and Safety Monitoring Board (DSMB) Approval to Increase RPE Dosage for Stargardt’s Disease Patients in U.S. Trial
- Research and Markets: Liver Transplantation Global Clinical Trials Review, H1, 2012 – provides elemental information and data relating to the clinical trials on Liver Transplantation
- Research and Markets: Anticoagulant Market – Large Atrial Fibrillation Population with Unmet Needs Will Help the U.S. Anticoagulant Market to Grow to $10 billion by 2016
Alliance Data Announces New Multi-year Agreement With Blue Nile, The Leading Online Retailer Of Diamonds And Fine Jewelry
Alliance Data to Launch and Manage Private Label Credit Card Program; Partnership to Focus on Driving Repeat Purchases and Customer Loyalty DALLAS, May 10, 2012 /PRNewswire/ -- Alliance Data Systems Corporation (NYSE: ADS), a leading provider of loyalty and marketing solutions derived from transaction-rich data, today announced it has signed a new multi-year agreement to create and manage a new private label credit card program for Blue Nile (NASDAQ: NILE; www.bluenile.com), the leading online ...continuedADS NILE software pharmaceutical CRM
Related News:
- Alliance Data Signs Multi-Year Renewal Agreement With Luxury Goods Retailer Little Switzerland
- Alliance Data Signs New Long-Term Agreement With Premier Designs Inc., a Leading Direct Sales and Service Company of High Fashion Jewelry
- Blue Nile Announces Fourth Quarter and Fiscal Year 2011 Financial Results
- Countries debate Nile River plans
- Alliance Data Provides Private Label Performance Update for March 2012
- Evotec AG Announces Multi-Year Agreement With The United States Environmental Protection Agency (EPA)
- Authenticom Enters Into Agreement with Kelley Blue Book to Become Licensed Provider of Automotive Valuation Data
Cryoport Teams with Pan Asia Logistics to Open Operations Center in Singapore
Cryoport, Inc. (OTCBB: CYRX) today announced that it has signed an agreement with Pan Asia Logistics to open its Asian Operations Center in Singapore. The agreement calls for Pan Asia to support the Cryoport Solution by providing warehousing, shipping, receiving, order entry and fulfillment, and refurbishing and recycling of Cryoport’s liquid nitrogen dry vapor shipping containers. “Shipments of life science and biological material are growing at a strong double digit growth rate in ...continuedCYRX cryogenic magazine pharmaceutical
Related News:
- CryoPort Announces Resignation of Chairman and Chief Executive Officer Larry Stambaugh
- Rehrig Pacific Logistics Opens Reverse Logistics and Recyclable Plastics Processing Center in Rancho Cucamonga, Cal.
- Global Growth Investor General Atlantic Opens Singapore Office, Expanding Focus in Southeast Asia
- Strong Attendance at the CoreNet Global Summit in Singapore Reflects Growth of Strategic Corporate Real Estate Practices in Asia
- New N2 Pressure Booster from Linde Helps Gas Injection Molders Improve Quality and Reduce Downtime
- Christophe Duchatellier Announced as Regional Head for Adecco Operations in Southeast and Northeast Asia
- Foster Wheeler Asia Pacific Awarded International Headquarters Award by the Singapore Economic Development Board
Teva Reports First Quarter 2012 Results
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today reported results for the quarter ended March 31, 2012. Highlights: Net revenues of $5.1 billion, compared to $4.1 billion in the first quarter of 2011, an increase of 25%. Non-GAAP operating income of $1.6 billion, an increase of 42% compared to $1.1 billion in the first quarter of 2011. Non-GAAP net income and Non-GAAP EPS of $1.3 billion and $1.47 diluted earnings per share, an increase of 39% and 41%, respectively, compared t...continuedTEVA pharmaceutical BETASERON pharma
Related News:
- Teva Reports Fourth Quarter and Full Year 2011 Results
- Teva to Report Fourth Quarter and Full Year 2011 Financial Results on February 15, 2012
- Teva to Report First Quarter 2012 Financial Results on May 9, 2012
- eBay Inc. Reports Strong First Quarter 2012 Results
- Hollysys Automation Technologies Reports Unaudited Financial Results for the Fiscal Year 2012 Second Quarter Ended December 31, 2011
- eBay Inc. Reports Strong Fourth Quarter and Full Year 2011 Results
- Harris Corporation Reports Fiscal 2012 Second Quarter Results
EpiCept Reports First Quarter 2012 Operating and Financial Results
Regulatory News: EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) today announced operating and financial results for the three months ended March 31, 2012, and provided an update on the Company’s key business initiatives. “EpiCept achieved an important milestone with respect to AmiKet™ during the first quarter of 2012,” stated Jack Talley, President and CEO of EpiCept. “Following a successful meeting with the U.S. Food and Drug Admini...continuedEPCT pharmaceutical Drugs epicept
Related News:
- EpiCept to Report First Quarter 2012 Operating and Financial Results on May 9, 2012
- EpiCept Corporation to Report Fourth Quarter and Full Year 2011 Operating and Financial Results on February 29, 2012
- Halozyme Reports First Quarter 2012 Financial Results
- Cipher Reports Fiscal 2011 Financial Results
- Incyte Reports 2011 Fourth-Quarter and Full-Year Financial Results; Provides 2012 Financial Guidance; Updates Shareholders on Key Clinical Programs
- Discovery Labs Reports Fourth Quarter Financial Results and Highlights Recent Milestones
- Antares Pharma Reports Fourth Quarter and Full Year 2011 Financial and Operating Results
Genta Initiates Randomized Trial of Tesetaxel in Gastric Cancer
-- TESEGAST Trial Opens in U.S., EU, and Asia -- Double-Blind Study Uses "All Oral" Chemotherapy Regimen as 2 nd -Line Treatment BERKELEY HEIGHTS, N.J., May 8, 2012 (GLOBE NEWSWIRE) -- announced today that the first patient has been accrued to a new randomized clinical trial of its lead compound, tesetaxel, in patients with advanced gastric cancer. The trial, known as TESEGAST, is a randomized, double-blind, placebo-controlled study that is expected to accrue approximately 260 patients....continuedGNTA exit rna pharmaceutical
Related News:
- Genta Initiates Randomized Trial of Tesetaxel in Gastric Cancer
- Advaxis Announces Cancer Research UK Initiates Phase 1/2 Clinical Trial of ADXS-HPV for the Treatment of Head and Neck Cancer
- Lixte Biotechnology Holdings Announces Submission of an IND to the FDA for Approval of a Clinical Trial of LB-100, a First-in-Class, Anti-Cancer Compound
- Genta Incorporated Reports Fourth Quarter and 2011 Year-End Financial Results
- Aeterna Zentaris Announces Top-Line Data from the Perifosine Phase 3 Trial in Refractory Advanced Colorectal Cancer
- Aeterna Zentaris Announces Top-Line Data from the Perifosine Phase 3 Trial in Refractory Advanced Colorectal Cancer
- Genta Appoints Dr. Brian Leyland-Jones and Richard J. Moran to Its Board of Directors
Pain Therapeutics Reports Q1 2012 Financial Results
AUSTIN, Texas, May 8, 2012 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported financial results for the quarter ended March 31, 2012. Net profit for Q1 2012 was $30,000, or $0.00 per share in Q1 2012, as compared to a net loss of $207,000, or $0.00 per share in Q1 2011. Cash and investments were $95.9 million at March 31, 2012. Net cash usage for the first half of 2012 continues to be expected to be under $5.0 million. The Company has no debt. Q1 2012...continuedPTIE pharmaceutical stock biotech
Related News:
- Harwood Feffer LLP Announces Investigation of Pain Therapeutics, Inc.
- United Therapeutics Corporation Reports First Quarter 2012 Financial Results
- Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2011 Financial Results
- Gentium Reports Fourth Quarter and Year End 2011 Financial Results
- Acorda Therapeutics Reports First Quarter 2012 Financial Results
- Trius Therapeutics Reports Fourth Quarter and Year End 2011 Financial Results
- UNISYS CORPORATION – Unisys Announces First-Quarter 2012 Financial Results
Genta Initiates Randomized Trial of Tesetaxel in Gastric Cancer
-- TESEGAST Trial Opens in U.S., EU, and Asia -- Double-Blind Study Uses "All Oral" Chemotherapy Regimen as 2 nd -Line Treatment BERKELEY HEIGHTS, N.J., May 8, 2012 (GLOBE NEWSWIRE) -- Genta Incorporated (OTCBB:GNTA) announced today that the first patient has been accrued to a new randomized clinical trial of its lead compound, tesetaxel, in patients with advanced gastric cancer. The trial, known as TESEGAST, is a randomized, double-blind, placebo-controlled study that is expected to ac...continuedGNTA antisense pharmaceutical Drugs
Related News:
- Advaxis Announces Cancer Research UK Initiates Phase 1/2 Clinical Trial of ADXS-HPV for the Treatment of Head and Neck Cancer
- Lixte Biotechnology Holdings Announces Submission of an IND to the FDA for Approval of a Clinical Trial of LB-100, a First-in-Class, Anti-Cancer Compound
- Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
- Pharmos Provides Update on Ongoing Clinical Trial of Levotofisopam for the Treatment of Gout
- Genta Appoints Dr. Brian Leyland-Jones and Richard J. Moran to Its Board of Directors
- Isotechnika Announces Agreement From the FDA on a Special Protocol Assessment for Its Phase 3 Voclosporin Trial
- Immunovaccine Vaccinates First Patient in Phase I Trial of the DPX-Survivac Cancer Vaccine
MFC Industrial Ltd. Announces Date Of Its First Quarter 2012 Earnings Release And Conference Call
NEW YORK, May 8, 2012 /PRNewswire/ -- MFC Industrial Ltd. (NYSE: MIL) (the "Company") announced plans to release its first quarter 2012 results before market on Tuesday, May 15, 2012. That same day, at 10:00 AM ET (7:00 AM PT), a conference call and webcast will be held to review the results; the call will be broadcast live over the Internet at the Company's website, www.mfcindustrial.com. Web participants are encouraged to go to the website at least 15 minutes prior to the start of th...continuedMIL antibody millipore pharmaceutical
Related News:
- MFC Industrial Ltd Announces Date of Its Year-End 2011 Earnings Release And Conference Call
- BJ’s Restaurants, Inc. Announces Date for First Quarter 2012 Earnings Release and Conference Call
- PAREXEL Announces Date of Second Quarter Fiscal Year 2012 Earnings Release and Conference Call
- Axion Power(tm) Announces Date Of Its First Quarter 2012 Earnings Release And Conference Call
- Health Care REIT, Inc. Announces Date of First Quarter 2012 Earnings Release, Conference Call and Webcast
- Cabot Oil & Gas Announces First Quarter 2012 Earnings Release Date and Conference Call
- Cabot Oil & Gas Announces First Quarter 2012 Earnings Release Date and Conference Call
Tortoise Capital Advisors Announces Distribution Dates and Amounts for Closed-End Funds
Certain closed-end funds managed by Tortoise Capital Advisors declared the following distributions today. The TYG, TYY, TYN, NTG and TTP distributions will be paid on June 1, 2012 to stockholders of record on May 23, 2012. For tax purposes, the ultimate characterization of distributions will be made after the determination of earnings and profits after year-end. For book purposes, the source of distributions for TYG, TYY, TYN and NTG is estimated to be 100 percent return of capital; the source of...continuedNTG TPZ TTP TYG TYN TYY Energy pharmaceutical llc
Related News:
- Tortoise Capital Advisors Announces Distribution Dates and Amounts for Closed-End Funds
- Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds
- Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds
- Dividend Dates and Distribution Amounts Announced for Certain BlackRock Closed-End Funds
- Eaton Vance Equity Income Closed-End Funds Declare Distributions and Announce Distribution Changes
- Tortoise Capital Resources Corp. Announces Second Quarter 2012 Distribution
- MFS Releases Closed-End Fund Income Distribution Sources for Certain Funds
Halozyme Reports First Quarter 2012 Financial Results
SAN DIEGO, May 7, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the quarter ended March 31, 2012. (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO) "We achieved a significant milestone in the first quarter with the European regulatory filing of the subcutaneous Herceptin program by our partner Roche," said Gregory I. Frost, Ph.D., President and Chief Executive Officer, Halozyme. "Despite the HyQ regulatory delay from ou...continuedHALO biotech pharmaceutical biopharmaceutical
Related News:
- Halozyme Reports Fourth Quarter and Year End 2011 Financial Results and Provides Guidance for 2012
- Halozyme to Host First Quarter 2012 Financial Results Conference Call
- Activision Blizzard Announces Record Fourth Quarter and Calendar Year 2011 Earnings
- Cullen/Frost Reports First Quarter Results
- DEQ Reports First Quarter 2012 Financial Results
- Tengion Provides Business Update and Reports First Quarter 2012 Financial Results
- Oxford Resource Partners, LP Reports Fourth Quarter and Full Year 2011 Financial Results
Morgan Stanley Smith Barney Congratulates Clients Gamesa, Google and Skanska on Global Equity Organization Industry Awards
The 13 annual Global Equity Organization conference focuses on the equity compensation industry; awarding firms for plan effectiveness, technology and other categories Morgan Stanley Smith Barney is pleased to announce that three of its stock plan clients were awarded prestigious Global Equity Organization (GEO) Awards at the 2012 ceremony in Washington, D.C., on April 17, 2012. 1 Founded in 1999, GEO is an international, not-for-profit organization designed to support equity compensation profes...continuedMS Financial pharmaceutical Brokers
Related News:
- Morgan Stanley Smith Barney Hosts Go Red Women’s Leadership Breakfast In Special Recognition of National Wear Red Day
- Morgan Stanley Alternative Investment Partners Raises $720 Million for Morgan Stanley Private Markets Fund V and $580 Million for Related Separate Accounts
- Yandex Announces Inducement Equity Awards in Connection With Acquisition
- Sheraton Atlanta General Manager Honored By Trumpet Awards Foundation
- Google to Present at the Morgan Stanley Technology, Media and Telecom Conference
- Women’s Bond Club Honors Carla Harris of Morgan Stanley and Kay Koplovitz, Founder, USA Network
- Thales Named Finalists in Info Security Products Guide Global Excellence Awards
AeroVironment Wins Port of Seattle Contract for Electric Ground Support Equipment Fast Charge Systems at Seattle-Tacoma International Airport
Electric Vehicle Symposium 26 – AeroVironment, Inc. (NASDAQ: AVAV) today announced the Port of Seattle has awarded the company a contract valued up to $8.8 million through 2014 to supply its PosiCharge™ electric Ground Support Equipment (eGSE) fast charge systems to the Seattle-Tacoma International Airport. PosiCharge (Photo: Business Wire) AeroVironment was selected following a rigorous competitive evaluation of multiple fast charge system suppliers. The PosiCharge eGSE fas...continuedAVAV Investors news pharmaceutical
Related News:
- West Coast Electric Highway Helps Kick the Gas Habit With First Electric Vehicle Fast-Charging Stations Along Interstate 5
- American Airlines To Launch New Service Between Seattle And Miami
- AeroVironment,(Inc. Announces Fiscal 2012 Third Quarter Results
- AeroVironment, Inc. Announces Establishment of 10b5-1 Trading Plan by Chief Executive Officer
- Balqon Corporation to Showcase Heavy Duty Electric Vehicles and Drive Systems at the 26th International Electric Vehicle Symposium in Los Angeles on May 6-9, 2012
- American Airlines To Launch New Service Between Miami And Seattle
- Governor Pat Quinn Rolls Out Nation’s Largest Electric Vehicle Fast-Charging Network
Unigene Announces First Quarter 2012 Financial Results
-Company's highest priority challenge to address debt and restructure balance sheet- BOONTON, N.J., May 7, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), today announced financial results for the first quarter ended March 31, 2012. First Quarter 2012 Financial Summary Unigene announced that its net loss for the three months ended March 31, 2012 decreased to $6.0 million or $(0.06) per share from $6.6 million or $(0.07) per share for the corresponding period in 2011. Reven...continuedUGNE pharmaceutical stocks osteoporosis
Related News:
- Unigene Announces Fourth Quarter and Full-Year 2011 Results
- Unigene Announces Key Appointments as Biotechnologies Strategic Business Unit Continues to Grow in 2012
- Unigene Provides 2012 Business Outlook
- CYS Investments, Inc. Announces First Quarter 2012 Financial Results
- Franklin Financial Corporation Reports Second Quarter 2012 Financial Results and Announces Share Repurchase Program
- Senior Housing Properties Trust Announces 2012 First Quarter Results
- Axcelis Announces Financial Results For First Quarter 2012
China Shenghuo Announces Receipt of Deficiency Notice and Voluntary Delisting from NYSE Amex LLC and Deregistration with the SEC
KUNMING, China, May 7, 2012 /PRNewswire-Asia-FirstCall/ -- China Shenghuo Pharmaceutical Holdings, Inc. (NYSE Amex LLC: KUN) ("China Shenghuo" or the "Company"), today announced its intent not to file Form 15 at this time and continue to be a reporting company until such time as it is allowed to suspend its reporting obligations. In a Press Release dated April 20, 2012, the Company announced its intention to file a Form 15, which would, upon such filing, suspend the Company's obligations to file cer...continuedKUN pharmaceutical Healthcare china
Related News:
- China Shenghuo Pharmaceutical Receives Opinion with Going Concern Qualification from its Auditor
- Orion Energy Systems, Inc. Receives Notice from NYSE Amex
- China North East Petroleum Receives NYSE Notice of Delisting for Alleged Failure to Satisfy a Continued Listing Rule or Standard
- American Oriental Bioengineering Inc. Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
- Cubic Energy, Inc. Receives Notice From NYSE Amex, LLC and Engages Donohoe Advisory Associates LLC
- Coastal Banking Company Announces Voluntary Deregistration From the SEC
- Enova Systems Receives NYSE Amex Exchange Compliance Notice
Quick-Med Technologies Licenses Stay Fresh(R) Antimicrobial Technology for Consumer Hosiery
Doris Hosiery Mills to Manufacture and Sell Stay Fresh Socks GAINESVILLE, Fla., May 7, 2012 (GLOBE NEWSWIRE) -- Quick-Med Technologies, Inc. (OTCQB:QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it has signed a Patent and Technology License Agreement with Doris Hosiery Mills, Limited. Under terms of the agreement, Doris will manufacture, distribute, market and sell consumer socks that incorporate Quick-Med's pro...continuedQMDT antibiotics pharmaceutical Technology
Related News:
- Roche and Life Technologies Corporation Sign New PCR IVD Licenses
- TransAct Technologies and ZINK Imaging Partner to Bring Full Color Zero Ink(R) Printing Technology to the Oil and Gas Industry
- BAE Systems Selects EPIR Technologies to Fabricate its Infrared Detector Array Technology.
- Zacks Sell List Highlights: Barnes & Noble, Rofin-Sinar Technologies, John Wiley & Sons and International Game Technology
- Sensus Gains Exclusive U.S. License for Innovative Consumer Energy Management Technology from Navetas
- Clean Coal Signs Technology License Agreement with Jindal Steel and Power Ltd.
- Kenneth Cole Announces Worldwide Licensing of Men’s Underwear, Women’s Intimates, Loungewear and Hosiery to Delta Galil